Publications

Cell

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

09-02-2017

Biomarker insights

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer.

17-12-2016

eLife

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

15-11-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

01-11-2016

The journal of pathology. Clinical research

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.

01-10-2016

Oncogene

Targeting the RB-E2F pathway in breast cancer.

15-09-2016

The New England journal of medicine

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

25-08-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

01-08-2016

Cancer research

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

01-08-2016

Annals of oncology : official journal of the European Society for Medical Oncology

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

01-08-2016

Oncotarget

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

21-06-2016

Nature biotechnology

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

01-06-2016

Molecular cancer research : MCR

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

01-05-2016

Cell

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

07-04-2016

Breast cancer research and treatment

Equivalence of MammaPrint array types in clinical trials and diagnostics.

01-04-2016

Oncogene

Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

03-03-2016

European urology

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

01-03-2016

Cancer discovery

DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

01-02-2016

Oncotarget

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

19-01-2016

Scientific reports

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

05-01-2016

Oncotarget

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

15-12-2015

Current colorectal cancer reports

Treatment Individualization in Colorectal Cancer.

01-12-2015

Nature medicine

The consensus molecular subtypes of colorectal cancer.

01-11-2015

Breast cancer research : BCR

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

03-10-2015

Molecular oncology

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

01-10-2015

Cell reports

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

29-09-2015

European urology

Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

01-08-2015

Cell research

A price to pay for tumor regression.

01-07-2015

Molecular oncology

Hurdles on the road to personalized medicine.

01-05-2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

20-04-2015

Cell research

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

01-04-2015

International journal of cancer

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

15-03-2015

Oncogene

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

22-01-2015

Cell cycle (Georgetown, Tex.)

Resistance to targeted cancer drugs through hepatocyte growth factor signaling.

27-11-2014

Proceedings of the National Academy of Sciences of the United States of America

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

21-10-2014

Trends in biochemical sciences

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.

01-10-2014

Molecular oncology

Drug resistance to targeted therapies: déjà vu all over again.

12-09-2014

Cell reports

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

11-09-2014

Cancer research

USP9X downregulation renders breast cancer cells resistant to tamoxifen.

15-07-2014

Molecular systems biology

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality.

01-07-2014

Cancer discovery

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

01-05-2014

Oncogene

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.

24-04-2014

Cell reports

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

10-04-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

Cancer discovery

Unlikely suspects identified in neuroblastoma conspiracy.

01-04-2014

Current opinion in genetics & development

Finding effective cancer therapies through loss of function genetic screens.

01-02-2014

Breast cancer research and treatment

Long-term impact of the 70-gene signature on breast cancer outcome.

01-02-2014

Molecular oncology

A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.

01-10-2013

Cell cycle (Georgetown, Tex.)

TGF-β: an emerging player in drug resistance.

15-09-2013

Breast cancer research and treatment

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.

01-08-2013